Deepak A Rao1, Kevin Wei1, Joseph F Merola1, William R O'Brien1, Samuel U Takvorian1, Paul F Dellaripa2, Peter H Schur2. 1. From the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School. 2. From the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School. pschur@partners.org pdellaripa@partners.org.
Abstract
OBJECTIVE: Concurrent testing for serum antineutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence (IF) and by antiproteinase 3 (PR3)/antimyeloperoxidase (MPO) antibody assays may identify patients with PR3-ANCA or MPO-ANCA despite a negative IF (IF-negative MPO/PR3-positive); however, the significance of this result is not clear. We sought to determine whether IF-negative, MPO/PR3-positive results identified any cases of clinically meaningful systemic vasculitis at our institution. METHODS: We conducted a retrospective chart review of all IF-negative, MPO/PR3-positive patients identified at our institution over a 2-year period. RESULTS: Of the 2345 samples tested over 2 years, 1998 were IF-negative. Among these IF-negative samples, 49 samples (2.5%) derived from 38 patients tested positive for MPO-ANCA or PR3-ANCA. Only 1 IF-negative, MPO/PR3-positive patient was subsequently diagnosed with ANCA-associated vasculitis (AAV). Eleven IF-negative, MPO/PR3-positive patients (29%) had been previously diagnosed and treated for AAV, all with positive IF and antibody tests prior to treatment. Four patients had evidence of cutaneous vasculitis not attributed to AAV, while several of the remaining IF-negative, MPO/PR3-positive patients had other immunologic disorders, including systemic lupus erythematosus (5 patients) and inflammatory bowel disease (3 patients). CONCLUSION: In this real-life cohort assayed simultaneously by IF and multiplexed bead assays, the detection of MPO-ANCA or PR3-ANCA without a positive IF rarely led to a new diagnosis of systemic vasculitis, and was more likely to occur in the context of a non-vasculitic inflammatory condition. Our results suggest that concurrent IF and MPO/PR3 testing may be of limited use in preventing a missed diagnosis of new-onset AAV.
OBJECTIVE: Concurrent testing for serum antineutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence (IF) and by antiproteinase 3 (PR3)/antimyeloperoxidase (MPO) antibody assays may identify patients with PR3-ANCA or MPO-ANCA despite a negative IF (IF-negative MPO/PR3-positive); however, the significance of this result is not clear. We sought to determine whether IF-negative, MPO/PR3-positive results identified any cases of clinically meaningful systemic vasculitis at our institution. METHODS: We conducted a retrospective chart review of all IF-negative, MPO/PR3-positive patients identified at our institution over a 2-year period. RESULTS: Of the 2345 samples tested over 2 years, 1998 were IF-negative. Among these IF-negative samples, 49 samples (2.5%) derived from 38 patients tested positive for MPO-ANCA or PR3-ANCA. Only 1 IF-negative, MPO/PR3-positive patient was subsequently diagnosed with ANCA-associated vasculitis (AAV). Eleven IF-negative, MPO/PR3-positive patients (29%) had been previously diagnosed and treated for AAV, all with positive IF and antibody tests prior to treatment. Four patients had evidence of cutaneous vasculitis not attributed to AAV, while several of the remaining IF-negative, MPO/PR3-positive patients had other immunologic disorders, including systemic lupus erythematosus (5 patients) and inflammatory bowel disease (3 patients). CONCLUSION: In this real-life cohort assayed simultaneously by IF and multiplexed bead assays, the detection of MPO-ANCA or PR3-ANCA without a positive IF rarely led to a new diagnosis of systemic vasculitis, and was more likely to occur in the context of a non-vasculitic inflammatory condition. Our results suggest that concurrent IF and MPO/PR3 testing may be of limited use in preventing a missed diagnosis of new-onset AAV.
Authors: J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik Journal: Am J Clin Pathol Date: 1999-04 Impact factor: 2.493
Authors: E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude Journal: Kidney Int Date: 1998-03 Impact factor: 10.612
Authors: Judy Savige; Wayne Dimech; Marvin Fritzler; James Goeken; E Chris Hagen; J Charles Jennette; Rob McEvoy; Charles Pusey; Wendy Pollock; Michelle Trevisin; Allan Wiik; Richard Wong Journal: Am J Clin Pathol Date: 2003-09 Impact factor: 2.493
Authors: R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne Journal: J Clin Invest Date: 1989-11 Impact factor: 14.808
Authors: Michelle Trevisin; Wendy Pollock; Wayne Dimech; Joy Melny; Bill Paspaliaris; David Gillis; Richard Wong; Judy Savige Journal: Am J Clin Pathol Date: 2008-01 Impact factor: 2.493